Toon Van Gorp

ORCID: 0000-0002-2564-721X · 14 papers in corpus
2026
British journal of cancer ·doi:10.1038/s41416-026-03509-8

BackgroundPrior studies have examined survival in patients with epithelial ovarian cancer (EOC); however, few consider race and ethnicity, particularly disaggregating Asian and Native Hawaiian/Pacific Islander women.MethodsWe analysed data …

2025
Life (Basel, Switzerland) ·doi:10.3390/life15020135

BackgroundCervical cancer (CC) is the fourth most common cancer diagnosis in women worldwide. Infection with high-risk human papillomavirus (HPV) is a critical but not determinative condition for CC development, as several co-factors modula…

article 2025
·doi:10.1016/j.ijgc.2024.100301
article 2024
Biomedicines ·doi:10.3390/biomedicines12020321

Interleukin-8 (IL-8) is involved in the regulation of inflammatory processes and carcinogenesis. Single-nucleotide polymorphisms (SNPs) within the IL-8 gene have been shown to alter the risks of lung, gastric, or hepatocellular carcinomas. …

other 2024
International journal of molecular sciences ·doi:10.3390/ijms251910272

Single nucleotide polymorphisms (SNPs) of the IL-16 gene have been reported to influence the risk of several cancers, but their role in ovarian cancer (OC) has not been studied. Using the restriction fragment length polymorphism (PCR-RFLP) …

2024
British journal of cancer ·doi:10.1038/s41416-024-02578-x

BackgroundSeveral diagnostic prediction models to help clinicians discriminate between benign and malignant adnexal masses are available. This study is a head-to-head comparison of the performance of the Assessment of Different NEoplasias i…

other 2023
Gynecologic Oncology ·doi:10.1016/j.ygyno.2022.10.018

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify fac…

2022
Cancers ·doi:10.3390/cancers14071780

Ovarian cancer (OC) is the most lethal genital malignancy in women. We aimed to develop and validate new proteomic-based models for non-invasive diagnosis of OC. We also compared them to the modified Risk of Ovarian Malignancy Algorithm (RO…

2021
Genome medicine ·doi:10.1186/s13073-021-00922-x

BackgroundHigh-grade serous tubo-ovarian cancer (HGSTOC) is characterised by extensive inter- and intratumour heterogeneity, resulting in persistent therapeutic resistance and poor disease outcome. Molecular subtype classification based on …

other 2021
Cellular and molecular life sciences : CMLS ·doi:10.1007/s00018-021-04023-1

Transient receptor potential (TRP) channels excel in cellular sensing as they allow rapid ion influx across the plasma membrane in response to a variety of extracellular cues. Recently, a distinct TRP mRNA expression signature was observed …

2013
BMC cancer ·doi:10.1186/1471-2407-13-178

BackgroundThe immune system is a key player in fighting cancer. Thus, we sought to identify a molecular 'immune response signature' indicating the presence of epithelial ovarian cancer (EOC) and to combine this with a serum protein biomarke…

2011
British journal of cancer ·doi:10.1038/sj.bjc.6606092

BackgroundRecently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secretory protein 4 (HE4) and CA125 successfully classified patients as presenting a high or low risk for epithelial ovarian cancer (EOC). We valid…

review 2004
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2003.03.001

For several decades, endometriosis has been suspected of playing a role in the aetiology of ovarian cancer. The literature concerning a possible histogenesis of ovarian cancer from benign endometriosis is reviewed in this chapter. Epidemiol…

review 2002
Maturitas ·doi:10.1016/s0378-5122(02)00031-2

Unopposed estrogens for treating menopausal symptoms were extensively used when epidemiological findings associated them with an increased endometrial cancer risk. Adding progestogens reverse this side effect efficiently but patient, dose, …